JP2020534253A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020534253A5 JP2020534253A5 JP2020506776A JP2020506776A JP2020534253A5 JP 2020534253 A5 JP2020534253 A5 JP 2020534253A5 JP 2020506776 A JP2020506776 A JP 2020506776A JP 2020506776 A JP2020506776 A JP 2020506776A JP 2020534253 A5 JP2020534253 A5 JP 2020534253A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- composition
- wing
- c9orf72
- repeat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762542778P | 2017-08-08 | 2017-08-08 | |
| US62/542,778 | 2017-08-08 | ||
| PCT/US2018/045653 WO2019032607A1 (en) | 2017-08-08 | 2018-08-07 | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020534253A JP2020534253A (ja) | 2020-11-26 |
| JP2020534253A5 true JP2020534253A5 (https=) | 2021-09-16 |
Family
ID=65271538
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020506814A Active JP7422068B2 (ja) | 2017-08-08 | 2018-08-07 | オリゴヌクレオチド組成物及びその方法 |
| JP2020506776A Pending JP2020534253A (ja) | 2017-08-08 | 2018-08-07 | オリゴヌクレオチド組成物及びその方法 |
| JP2023161596A Pending JP2024009824A (ja) | 2017-08-08 | 2023-09-25 | オリゴヌクレオチド組成物及びその方法 |
| JP2025154621A Pending JP2026016363A (ja) | 2017-08-08 | 2025-09-18 | オリゴヌクレオチド組成物及びその方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020506814A Active JP7422068B2 (ja) | 2017-08-08 | 2018-08-07 | オリゴヌクレオチド組成物及びその方法 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023161596A Pending JP2024009824A (ja) | 2017-08-08 | 2023-09-25 | オリゴヌクレオチド組成物及びその方法 |
| JP2025154621A Pending JP2026016363A (ja) | 2017-08-08 | 2025-09-18 | オリゴヌクレオチド組成物及びその方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (3) | US20200362337A1 (https=) |
| EP (2) | EP3664816A4 (https=) |
| JP (4) | JP7422068B2 (https=) |
| KR (1) | KR20200035301A (https=) |
| CN (2) | CN110996968A (https=) |
| AR (1) | AR112779A1 (https=) |
| AU (1) | AU2018316159A1 (https=) |
| CA (1) | CA3072076A1 (https=) |
| SG (1) | SG11202000274RA (https=) |
| TW (1) | TW201920672A (https=) |
| WO (2) | WO2019032607A1 (https=) |
Families Citing this family (68)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102213609B1 (ko) | 2012-07-13 | 2021-02-08 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| PL2872485T3 (pl) | 2012-07-13 | 2021-05-31 | Wave Life Sciences Ltd. | Asymetryczna grupa pomocnicza |
| BR112016016400A2 (pt) | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
| RU2708237C2 (ru) | 2014-08-22 | 2019-12-05 | Общество с ограниченной ответственностью "НооГен" | Модифицированные олигонуклеотиды и способ их получения |
| IL320434A (en) | 2015-07-22 | 2025-06-01 | Wave Life Sciences Ltd | Oligonucleotide preparations and methods |
| IL295755A (en) | 2015-10-09 | 2022-10-01 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods thereof |
| CN108779132B (zh) | 2016-03-13 | 2022-04-15 | 波涛生命科学有限公司 | 用于亚磷酰胺和寡核苷酸合成的组合物和方法 |
| EP3452596A4 (en) | 2016-05-04 | 2020-03-18 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS |
| JP2019520339A (ja) | 2016-06-03 | 2019-07-18 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド、その組成物および方法 |
| WO2017220751A1 (en) | 2016-06-22 | 2017-12-28 | Proqr Therapeutics Ii B.V. | Single-stranded rna-editing oligonucleotides |
| CN110352244B (zh) | 2016-09-01 | 2023-03-21 | ProQR治疗上市公司Ⅱ | 化学修饰的编辑rna的单链寡核苷酸 |
| US11873316B2 (en) | 2016-11-23 | 2024-01-16 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| US11723912B2 (en) | 2016-12-08 | 2023-08-15 | University Of Utah Research Foundation | Staufen1 agents and associated methods |
| JP2020522510A (ja) | 2017-06-02 | 2020-07-30 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド組成物及びその使用方法 |
| CA3065523A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| US11718638B2 (en) | 2017-06-21 | 2023-08-08 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
| EP3664816A4 (en) | 2017-08-08 | 2021-05-19 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED PROCESSES |
| CA3072110A1 (en) | 2017-09-18 | 2019-03-21 | Wave Life Sciences Ltd. | Technologies for oligonucleotide preparation |
| EP3694530A4 (en) | 2017-10-12 | 2021-06-30 | Wave Life Sciences Ltd. | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
| WO2019157531A1 (en) | 2018-02-12 | 2019-08-15 | Ionis Pharmaceuticals, Inc. | Modified compounds and uses thereof |
| SG11202009877XA (en) | 2018-04-12 | 2020-11-27 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods of use thereof |
| US12391942B2 (en) | 2018-05-11 | 2025-08-19 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| GB201808146D0 (en) | 2018-05-18 | 2018-07-11 | Proqr Therapeutics Ii Bv | Stereospecific Linkages in RNA Editing Oligonucleotides |
| EP3807291A4 (en) * | 2018-06-14 | 2022-02-23 | University of Utah Research Foundation | STAUFEN1 REGULATORY AGENTS AND ASSOCIATED PROCEDURES |
| US12429487B2 (en) | 2018-12-06 | 2025-09-30 | Biogen Ma Inc. | Neurofilament protein for guiding therapeutic intervention in amyotrophic lateral sclerosis |
| CN113423385A (zh) * | 2019-02-01 | 2021-09-21 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| JP2022525541A (ja) | 2019-03-20 | 2022-05-17 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド調製に有用な技術 |
| US12595479B2 (en) * | 2019-03-20 | 2026-04-07 | President And Fellows Of Harvard College | Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases |
| US11629347B2 (en) | 2019-05-06 | 2023-04-18 | University Of Massachusetts | Anti-C9ORF72 oligonucleotides and related methods |
| EP3965780A4 (en) * | 2019-05-09 | 2023-10-25 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE |
| EP3994159A4 (en) * | 2019-07-05 | 2023-08-09 | University of Florida Research Foundation, Incorporated | METHODS OF TREATING NEUROLOGICAL DISEASES ASSOCIATED WITH THE RAN PROTEIN |
| JP2022550915A (ja) * | 2019-10-06 | 2022-12-05 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物及びその使用方法 |
| WO2021155067A1 (en) * | 2020-01-28 | 2021-08-05 | University Of Southern California | Compositions and methods to treat neurological diseases |
| WO2021159008A2 (en) | 2020-02-07 | 2021-08-12 | Maze Therapeutics, Inc. | Compositions and methods for treating neurodegenerative diseases |
| BR112022020412A2 (pt) * | 2020-04-09 | 2023-05-02 | Association Inst De Myologie | Sequências antissenso para tratar esclerose lateral amiotrófica |
| MX2022014606A (es) | 2020-05-22 | 2023-03-08 | Wave Life Sciences Ltd | Composiciones de oligonucleótidos bicatenarios y métodos relacionados con las mismas. |
| EP4320236A1 (en) | 2021-04-06 | 2024-02-14 | Maze Therapeutics, Inc. | Compositions and methods for treating tdp-43 proteinopathy |
| EP4347822A2 (en) * | 2021-06-04 | 2024-04-10 | Alnylam Pharmaceuticals, Inc. | Human chromosome 9 open reading frame 72 (c9orf72) irna agent compositions and methods of use thereof |
| EP4479535A1 (en) | 2022-02-14 | 2024-12-25 | ProQR Therapeutics II B.V. | Guide oligonucleotides for nucleic acid editing in the treatment of hypercholesterolemia |
| EP4522742A2 (en) | 2022-05-13 | 2025-03-19 | Alnylam Pharmaceuticals, Inc. | Single-stranded loop oligonucleotides |
| US20260027237A1 (en) | 2022-07-15 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Chemically modified oligonucleotides for adar-mediated rna editing |
| JP2025524566A (ja) | 2022-07-15 | 2025-07-30 | プロキューアール セラピューティクス ツー ベスローテン フェンノートシャップ | Ａｄａｒ媒介ｒｎａ編集のためのオリゴヌクレオチドおよびその使用 |
| AU2023356317A1 (en) | 2022-10-05 | 2025-05-15 | Trace Neuroscience, Inc. | Unc13a antisense oligonucleotides and uses thereof |
| GB202215614D0 (en) | 2022-10-21 | 2022-12-07 | Proqr Therapeutics Ii Bv | Heteroduplex rna editing oligonucleotide complexes |
| WO2024110565A1 (en) | 2022-11-24 | 2024-05-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of hereditary hfe-hemochromatosis |
| GB202218090D0 (en) | 2022-12-01 | 2023-01-18 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of aldehyde dehydrogenase 2 deficiency |
| AU2023390632A1 (en) | 2022-12-09 | 2025-07-10 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of cardiovascular disease |
| GB202300865D0 (en) | 2023-01-20 | 2023-03-08 | Proqr Therapeutics Ii Bv | Delivery of oligonucleotides |
| WO2024175550A1 (en) | 2023-02-20 | 2024-08-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of atherosclerotic cardiovascular disease |
| KR102599078B1 (ko) | 2023-03-21 | 2023-11-06 | 고아라 | 큐티클 케어 세트 및 이를 이용한 큐티클 케어 방법 |
| EP4689110A1 (en) | 2023-03-24 | 2026-02-11 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| GB202304363D0 (en) | 2023-03-24 | 2023-05-10 | Proqr Therapeutics Ii Bv | Chemically modified antisense oligonucleotides for use in RNA editing |
| EP4688143A1 (en) | 2023-03-27 | 2026-02-11 | ProQR Therapeutics II B.V. | Antisense oligonucleotides for the treatment of liver disease |
| EP4709855A2 (en) | 2023-05-12 | 2026-03-18 | Alnylam Pharmaceuticals, Inc. | Single-stranded loop oligonucleotides |
| TW202516003A (zh) | 2023-06-16 | 2025-04-16 | 荷蘭商Ｐｒｏｑｒ治療上市公司Ｉｉ | 用於治療神經退化性疾病之反義寡核苷酸 |
| WO2025015335A1 (en) | 2023-07-13 | 2025-01-16 | Korro Bio, Inc. | Rna-editing oligonucleotides and uses thereof |
| WO2025051946A1 (en) | 2023-09-07 | 2025-03-13 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2025096809A1 (en) | 2023-10-31 | 2025-05-08 | Korro Bio, Inc. | Oligonucleotides comprising phosphoramidate internucleotide linkages |
| WO2025104239A1 (en) | 2023-11-16 | 2025-05-22 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of classic galactosemia |
| WO2025128799A1 (en) | 2023-12-12 | 2025-06-19 | Korro Bio, Inc. | Double-stranded rna-editing oligonucleotides and uses thereof |
| WO2025132708A1 (en) | 2023-12-20 | 2025-06-26 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of huntington's disease |
| GB202404661D0 (en) | 2024-04-02 | 2024-05-15 | Proqr Therapeutics Ii Bv | Antisense oligoncleotides for the treatment of liver disease |
| WO2025224230A1 (en) | 2024-04-25 | 2025-10-30 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of fatty liver disease |
| GB202410081D0 (en) | 2024-07-11 | 2024-08-28 | Proqr Therapeutics Ii Bv | Antisense oligonucleotides for the treatment of cardiovascular disease |
| WO2026022136A1 (en) | 2024-07-23 | 2026-01-29 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of metabolic disorders |
| WO2026050243A1 (en) | 2024-08-26 | 2026-03-05 | Korro Bio, Inc. | Galnac conjugated oligonucleotides for rna editing |
| WO2026060374A2 (en) | 2024-09-16 | 2026-03-19 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of neurological disorders |
| WO2026068781A1 (en) | 2024-09-30 | 2026-04-02 | Proqr Therapeutics Ii B.V. | Antisense oligonucleotides for the treatment of liver disease |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6242589B1 (en) * | 1998-07-14 | 2001-06-05 | Isis Pharmaceuticals, Inc. | Phosphorothioate oligonucleotides having modified internucleoside linkages |
| US6867295B2 (en) * | 2001-09-07 | 2005-03-15 | Dionex Corporation | Ion exchange cryptands covalently bound to substrates |
| JP4348044B2 (ja) | 2002-02-12 | 2009-10-21 | 株式会社キラルジェン | 立体規則性の高いジヌクレオシドホスホロチオエートの製造法 |
| US8101348B2 (en) | 2002-07-10 | 2012-01-24 | Max-Planck-Gesellschaft Zur Foerderung Der Wissenschaften E.V. | RNA-interference by single-stranded RNA molecules |
| AU2003261449A1 (en) | 2002-08-07 | 2004-02-25 | Compositions for rna interference and methods of use thereof | |
| JP2005089441A (ja) | 2003-08-08 | 2005-04-07 | Toudai Tlo Ltd | 立体規則性の高いリン原子修飾ヌクレオチド類縁体の製造法 |
| JP4580870B2 (ja) | 2003-09-02 | 2010-11-17 | 株式会社キラルジェン | リボヌクレオチド又はリボヌクレオチド誘導体の製造方法 |
| JP4616175B2 (ja) | 2003-09-02 | 2011-01-19 | 株式会社キラルジェン | ５’−ホスフィチル化モノマーおよびｈ−ホスホネートオリゴヌクレオチド誘導体の製造方法 |
| WO2005070859A1 (ja) | 2004-01-27 | 2005-08-04 | Takeshi Wada | フルオラス担体およびそれを用いたオリゴヌクレオチド誘導体の製造方法 |
| WO2005085272A1 (ja) | 2004-03-05 | 2005-09-15 | Takeshi Wada | ボラノホスフェートモノマーおよびそれを用いたオリゴヌクレオチド誘導体の製造方法 |
| WO2005092909A1 (ja) | 2004-03-25 | 2005-10-06 | Toudai Tlo, Ltd. | 立体規則性の高いリボヌクレオチド類縁体及びデオキシリボヌクレオチド類縁体の製造法 |
| ES2526295T5 (es) | 2006-10-18 | 2021-05-04 | Ionis Pharmaceuticals Inc | Compuestos antisentido |
| CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
| RU2612521C2 (ru) | 2009-07-06 | 2017-03-09 | Онтории, Инк. | Новые пролекарства нуклеиновых кислот и способы их применения |
| ES2586683T3 (es) | 2009-09-16 | 2016-10-18 | Wave Life Sciences Japan, Inc. | Grupo protector novedoso para sintetizar ARN y derivados del mismo |
| CA2789038A1 (en) * | 2010-02-08 | 2011-08-11 | Isis Pharmaceuticals, Inc. | Selective reduction of allelic variants |
| JP5847700B2 (ja) | 2010-03-05 | 2016-01-27 | 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ | リボヌクレオシドホスホロチオエートの製造方法 |
| WO2012027033A1 (en) * | 2010-07-19 | 2012-03-01 | Isis Pharmaceuticals, Inc. | Compounds and methods for modulating target nuclear and sub-nuclear nucleic acid molecules in cells and animals |
| JP5868324B2 (ja) | 2010-09-24 | 2016-02-24 | 株式会社Wave Life Sciences Japan | 不斉補助基 |
| JP6093924B2 (ja) | 2010-11-30 | 2017-03-15 | 株式会社Wave Life Sciences Japan | ２’−ｏ−修飾ｒｎａ |
| CN103796657B (zh) | 2011-07-19 | 2017-07-11 | 波涛生命科学有限公司 | 合成官能化核酸的方法 |
| US9896729B2 (en) | 2011-08-31 | 2018-02-20 | The University Of Manchester | Method for diagnosing a neurodegenerative disease |
| WO2013119979A1 (en) * | 2012-02-08 | 2013-08-15 | Isis Pharmaceuticals, Inc. | Methods and compositions for modulating factor vii expression |
| WO2013159108A2 (en) * | 2012-04-20 | 2013-10-24 | Isis Pharmaceuticals, Inc. | Oligomeric compounds comprising bicyclic nucleotides and uses thereof |
| PL2872485T3 (pl) | 2012-07-13 | 2021-05-31 | Wave Life Sciences Ltd. | Asymetryczna grupa pomocnicza |
| KR102213609B1 (ko) | 2012-07-13 | 2021-02-08 | 웨이브 라이프 사이언시스 리미티드 | 키랄 제어 |
| CA2879066C (en) | 2012-07-13 | 2019-08-13 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant |
| ES2762326T5 (es) * | 2012-10-15 | 2023-04-27 | Ionis Pharmaceuticals Inc | Métodos para modular la expresión de C9ORF72 |
| US10221414B2 (en) | 2013-10-11 | 2019-03-05 | Ionis Pharmaceuticals, Inc. | Compositions for modulating C9ORF72 expression |
| JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
| US10322173B2 (en) | 2014-01-15 | 2019-06-18 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having anti-allergic activity, and anti-allergic agent |
| JPWO2015108047A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 免疫誘導活性を有するキラル核酸アジュバンド及び免疫誘導活性剤 |
| BR112016016400A2 (pt) * | 2014-01-16 | 2017-10-03 | Wave Life Sciences Ltd | Composições de oligonucleotídeos quiralmente controlados, seu uso, sua composição farmacêutica, e métodos |
| WO2015168172A1 (en) * | 2014-04-28 | 2015-11-05 | Isis Pharmaceuticals, Inc. | Linkage modified oligomeric compounds |
| WO2016024205A1 (en) * | 2014-08-15 | 2016-02-18 | Pfizer Inc. | Oligomers targeting hexanucleotide repeat expansion in human c9orf72 gene |
| AU2016222546B2 (en) * | 2015-02-26 | 2020-01-23 | Ionis Pharmaceuticals, Inc. | Allele specific modulators of P23H rhodopsin |
| RS60230B1 (sr) * | 2015-04-16 | 2020-06-30 | Ionis Pharmaceuticals Inc | Kompozicije za moduliranje ekspresije c9orf72 |
| IL320434A (en) | 2015-07-22 | 2025-06-01 | Wave Life Sciences Ltd | Oligonucleotide preparations and methods |
| IL295755A (en) | 2015-10-09 | 2022-10-01 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods thereof |
| WO2017079291A1 (en) | 2015-11-02 | 2017-05-11 | Ionis Pharmaceuticals, Inc. | Compounds and methods for modulating c90rf72 |
| CN108779132B (zh) | 2016-03-13 | 2022-04-15 | 波涛生命科学有限公司 | 用于亚磷酰胺和寡核苷酸合成的组合物和方法 |
| US20190142856A1 (en) | 2016-04-13 | 2019-05-16 | Ionis Pharmaceuticals, Inc. | Methods for reducing c9orf72 expression |
| EP3452596A4 (en) * | 2016-05-04 | 2020-03-18 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED METHODS |
| CN109462995A (zh) | 2016-05-04 | 2019-03-12 | 波涛生命科学有限公司 | 生物活性剂的方法和组合物 |
| JP2019520339A (ja) | 2016-06-03 | 2019-07-18 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド、その組成物および方法 |
| WO2018022473A1 (en) | 2016-07-25 | 2018-02-01 | Wave Life Sciences Ltd. | Phasing |
| US11873316B2 (en) | 2016-11-23 | 2024-01-16 | Wave Life Sciences Ltd. | Compositions and methods for phosphoramidite and oligonucleotide synthesis |
| JP2020522510A (ja) | 2017-06-02 | 2020-07-30 | ウェイブ ライフ サイエンシズ リミテッドＷａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｌｔｄ． | オリゴヌクレオチド組成物及びその使用方法 |
| CN120330183A (zh) | 2017-06-02 | 2025-07-18 | 波涛生命科学有限公司 | 寡核苷酸组合物及其使用方法 |
| CA3065523A1 (en) | 2017-06-02 | 2018-12-06 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| US11718638B2 (en) | 2017-06-21 | 2023-08-08 | Wave Life Sciences Ltd. | Compounds, compositions and methods for synthesis |
| WO2019002237A1 (en) | 2017-06-28 | 2019-01-03 | Roche Innovation Center Copenhagen A/S | METHOD OF MULTIPLE COUPLING AND OXIDATION |
| EP3664816A4 (en) | 2017-08-08 | 2021-05-19 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND RELATED PROCESSES |
| CA3072110A1 (en) | 2017-09-18 | 2019-03-21 | Wave Life Sciences Ltd. | Technologies for oligonucleotide preparation |
| EP3694530A4 (en) | 2017-10-12 | 2021-06-30 | Wave Life Sciences Ltd. | COMPOSITIONS OF OLIGONUCLEOTIDES AND RELATED PROCESSES |
| SG11202009877XA (en) | 2018-04-12 | 2020-11-27 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods of use thereof |
| US12391942B2 (en) | 2018-05-11 | 2025-08-19 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods of use thereof |
| JP2022513719A (ja) | 2018-12-06 | 2022-02-09 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物及びその方法 |
| CN113423385A (zh) | 2019-02-01 | 2021-09-21 | 波涛生命科学有限公司 | 寡核苷酸组合物及其方法 |
| JP2022525541A (ja) | 2019-03-20 | 2022-05-17 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド調製に有用な技術 |
| WO2020196662A1 (ja) | 2019-03-25 | 2020-10-01 | 国立大学法人東京医科歯科大学 | 二本鎖核酸複合体及びその使用 |
| BR112021021203A2 (pt) | 2019-04-25 | 2022-01-04 | Wave Life Sciences Ltd | Oligonucleotídeo; composição de oligonucleotídeo quiralmente controlada; composição farmacêutica; método para prevenir, tratar ou melhorar uma afecção, distúrbio ou doença relacionada a ush2a e/ou prevenir, atrasar o início, desenvolvimento e/ou progresso, e/ou tratar uma afecção, distúrbio ou doença relacionada a ush2a em um indivíduo suscetível à mesma ou que sofre da mesma; método para aumentar o nível de salto de um éxon prejudicial em uma transcrição de gene ush2a ou seu produto de gene em uma célula; método para prevenir, atrasar o início ou progressão de, tratar ou melhorar uma afecção, distúrbio ou doença relacionada a ush2a em um indivíduo suscetível à mesma ou que sofre da mesma; método para saltar um éxon prejudicial 13 em um alelo de ush2a em um indivíduo; método para produzir ou aumentar o nível de um éxon de proteína ush2a com salto 13 em um sistema; e composto, oligonucleotídeo, composição ou método |
| SG11202111387YA (en) | 2019-04-25 | 2021-11-29 | Wave Life Sciences Ltd | Oligonucleotide compositions and methods of use thereof |
| EP3965780A4 (en) | 2019-05-09 | 2023-10-25 | Wave Life Sciences Ltd. | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS OF USE |
| JP7766589B2 (ja) | 2019-10-06 | 2025-11-10 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物及びその使用方法 |
| JP2022550915A (ja) | 2019-10-06 | 2022-12-05 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物及びその使用方法 |
| JP2023515862A (ja) | 2020-03-01 | 2023-04-14 | ウェイブ ライフ サイエンシズ リミテッド | オリゴヌクレオチド組成物及びその方法 |
| AU2021277407A1 (en) | 2020-05-22 | 2022-11-17 | Wave Life Sciences Ltd. | Oligonucleotide compositions and methods thereof |
| WO2022046667A1 (en) | 2020-08-24 | 2022-03-03 | Wave Life Sciences Ltd. | Cells and non-human animals engineered to express adar1 and uses thereof |
| WO2022046723A1 (en) | 2020-08-24 | 2022-03-03 | Wave Life Sciences Ltd. | Immunoassays for detecting wild type huntingtin protein and methods of treatment employing such immunoassays |
| KR20230118716A (ko) | 2020-11-08 | 2023-08-11 | 웨이브 라이프 사이언시스 리미티드 | 올리고뉴클레오티드 조성물 및 이의 방법 |
-
2018
- 2018-08-07 EP EP18844660.3A patent/EP3664816A4/en not_active Withdrawn
- 2018-08-07 AR ARP180102248A patent/AR112779A1/es unknown
- 2018-08-07 CN CN201880051313.6A patent/CN110996968A/zh active Pending
- 2018-08-07 CN CN201880052699.2A patent/CN111032057A/zh active Pending
- 2018-08-07 KR KR1020207006702A patent/KR20200035301A/ko not_active Ceased
- 2018-08-07 SG SG11202000274RA patent/SG11202000274RA/en unknown
- 2018-08-07 WO PCT/US2018/045653 patent/WO2019032607A1/en not_active Ceased
- 2018-08-07 CA CA3072076A patent/CA3072076A1/en active Pending
- 2018-08-07 WO PCT/US2018/045659 patent/WO2019032612A1/en not_active Ceased
- 2018-08-07 US US16/636,900 patent/US20200362337A1/en not_active Abandoned
- 2018-08-07 EP EP18842985.6A patent/EP3664815A4/en active Pending
- 2018-08-07 JP JP2020506814A patent/JP7422068B2/ja active Active
- 2018-08-07 US US16/636,902 patent/US11739325B2/en active Active
- 2018-08-07 TW TW107127371A patent/TW201920672A/zh unknown
- 2018-08-07 JP JP2020506776A patent/JP2020534253A/ja active Pending
- 2018-08-07 AU AU2018316159A patent/AU2018316159A1/en not_active Abandoned
-
2023
- 2023-09-25 JP JP2023161596A patent/JP2024009824A/ja active Pending
-
2024
- 2024-03-21 US US18/613,034 patent/US20250066775A1/en active Pending
-
2025
- 2025-09-18 JP JP2025154621A patent/JP2026016363A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020534253A5 (https=) | ||
| JP2022550915A5 (https=) | ||
| JP2022532169A5 (https=) | ||
| CN111936163B (zh) | 用于治疗基于无义介导的rna衰变的病况和疾病的反义寡聚体 | |
| JP2016513976A5 (https=) | ||
| JP2024009824A5 (https=) | ||
| JP7129702B2 (ja) | オーバーハングを有する二本鎖核酸複合体 | |
| JP2026069566A (ja) | タウ発現を調節するための組成物 | |
| JP7054675B2 (ja) | 網膜色素変性症１８と網膜色素変性症１３の処置のための組成物と方法 | |
| TWI901675B (zh) | 用於病症及疾病之治療的opa1反義寡聚物 | |
| JP2023515862A5 (https=) | ||
| US10273474B2 (en) | Methods for modulating Tau expression for reducing seizure and modifying a neurodegenerative syndrome | |
| JP2017536338A5 (https=) | ||
| JP2012525851A5 (https=) | ||
| JP2018513682A5 (https=) | ||
| CA3162618A1 (en) | Antisense oligonucleotide-based progranulin augmentation therapy in neurodegenerative diseases | |
| JP2009537129A (ja) | エキソンスキッピングを誘発する為の手段及び方法 | |
| JP2015511494A5 (https=) | ||
| US20170211064A1 (en) | Compositions and methods for modulating tau expression | |
| WO2017219017A1 (en) | Modulation of gys1 expression | |
| AU2013256471A1 (en) | Organic compositions to treat KRAS-related diseases | |
| JP2017510583A (ja) | 遺伝子サイレンシング用トランスサイレチン対立遺伝子選択的ｕｎａオリゴマー | |
| JP2022500079A5 (https=) | ||
| TW202136511A (zh) | 能進行外顯子跳讀之反義核酸 | |
| JP2025518487A5 (https=) |